The role of the conditioning regimen for autologous and ex vivo genetically modified hematopoietic stem cell-based therapies: Recommendations from the ISCT stem cell engineering committee Review


Authors: Oved, J. H.; Russell, A.; DeZern, A.; Prockop, S. E.; Bonfim, C.; Sharma, A.; Purtill, D.; Lakkaraja, M.; Bidgoli, A.; Bhoopalan, S. V.; Soni, S.; Boelens, J. J.; Abraham, A.
Review Title: The role of the conditioning regimen for autologous and ex vivo genetically modified hematopoietic stem cell-based therapies: Recommendations from the ISCT stem cell engineering committee
Abstract: Background: The advent of autologous gene modified cell therapies to treat monogenic disorders has been a major step forward for the field of hematopoietic stem cell transplantation (HCT) and cellular therapies. The need for disease-specific conditioning to enable these products to provide a potential cure has required extrapolation from experience in myeloablative and non-myeloablative HCT for these disorders. Methods: In this manuscript, we review the current datasets and clinical experience using different conditioning regimens for autologous gene therapies in hemoglobinopathies, metabolic and lysosomal disorders, inborn errors of immunity (IEI) and bone marrow failure (BMF) syndromes. Results: The disease specific and unique conditioning requirements of each disorder are considered in order to achieve maximal benefit while minimizing associated toxicities. Conclusions: Standardized recommendations based on these data are made for each set of disorders to harmonize treatment. Future directions and the possibility of non-genotoxic conditioning regimens for autologous gene therapies are also discussed. Ethical Statement: The authors followed all relevant ethical considerations in writing this manuscript. © 2024 International Society for Cell & Gene Therapy
Keywords: stem cell transplant; hematopoietic stem cell transplantation; information processing; gene therapy; ex vivo study; metabolic disorder; immunopathology; bone marrow depression; hemoglobinopathy; conditioning; cell engineering; myeloablation; human; article; inborn errors of immunity; lysosomal disease
Journal Title: Cytotherapy
Volume: 27
Issue: 1
ISSN: 1465-3249
Publisher: Elsevier Science Ltd.  
Date Published: 2025-01-01
Start Page: 78
End Page: 84
Language: English
DOI: 10.1016/j.jcyt.2024.09.001
PUBMED: 39320295
PROVIDER: scopus
DOI/URL:
Notes: The MSK Cancer Center Support Grant (P30 CA008748) is acknowledge in the PDF -- Corresponding authors is MSK author: Joseph H. Oved -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Jaap Jan Boelens
    213 Boelens
  2. Joseph Hai Oved
    36 Oved